Company

Location

Amt. (M)

Details

Date

TOTAL: $736.5M

ADC Therapeutics Sarl

London

$80

ADC raised $80M in a private round supported by Auven Therapeutics, Astrazeneca plc and new U.S. and European investors

9/3/15

Alector LLC

San Francisco

$32

Alector raised $32M in a series C financing led by MRL Ventures with participation from Orbimed, Polaris Partners, Google Ventures, Topspin Partners, Mission Bay Capital and others

9/17/15

Apitope Ltd.

Cardiff, UK

$13.5

Apitope raised €12M (US$13.5M) in a series B financing led by new investor Wales Life Sciences Fund and current investors Vesalius Biocapital, LRM, PMV and Wyvern

9/30/15

Aptinyx Inc. (spinout of Naurex Inc.)

Evanston, Ill.

ND

Aptinyx received a substantial seed round

9/16/15

Artax Biopharma Inc.

Cambridge, Mass.

$10

Artax raised $10M in a series B round led by former Genzyme CEO Henri Termeer and Advent Life Sciences; existing investors, including A.M. Pappas, also participated

9/22/15

Asceneuron SA

Lausanne, Switzerland

$30.6

Asceneuron SA closed a series A round of CHF30M (US$30.6M) led by Sofinnova Partners, which was joined by new investors SR One, Kurma Partners and Johnson & Johnson Innovation

9/30/15

Ascletis Inc.

Hangzhou, China

$35

Ascletis completed a $35M financing led by C-Bridge Capital, joined by Tasly Pharmaceutical and Pavilion Capital

9/2/15

Audion Therapeutics BV

Amsterdam

$2.8

Audion received a €2.5M (US$2.8M) series B investment from Inkef Capital

9/9/15

Avexis Inc.

Chicago

$65

Avexis completed a $65M class D common stock financing led by funds and accounts managed by T. Rowe Price Associates Inc.; other investors were Janus Capital Management LLC, Adage Capital Management L.P., RA Capital Management, QVT Financial LP, Rock Springs Capital Management LP, Foresite Capital Management LLC, RTW Investments LLC and Boxer Capital of Tavistock Life Sciences, as well as existing investors Deerfield Management, Roche Venture Fund and Venrock

9/10/15

Cognition Therapeutics Inc.

Pittsburgh

$12

Cognition completed a series B preferred stock financing totaling $12M led by Golden Seeds, which included Bios Memory SPV1, Cowtown Angels, Scale Investors, Dolby Family Ventures and Maine Angels, as well as additional life sciences investors; existing investors Ogden CAP, PLSG Accelerator Fund, Tech Coast Angels, ACE Fund, Ariel Southeast Angel Partners and M5Invest Partners also participated

9/9/15

Corvus Pharmaceuticals Inc.

Burlingame, Calif.

$75

Corvus raised $75M in a series B round from a syndicate led by Rock Springs Capital Management that included Fidelity Management and Research Co., Blackrock, accounts managed by T. Rowe Price, Jennison Associates on behalf of certain clients, Roche Venture Fund, Cormorant Asset Management, Sphera Funds Management, Venbio Select and Cowen Private Investments; the company's founding investors – Orbimed, Novo Ventures and Adams Street Partners – also participated in the round

9/30/15

Deciphera Pharmaceuticals LLC

Lawrence, Kan.

$75

Deciphera raised $75M in a series B round led by New Leaf Venture Partners

9/22/15

Intellia Therapeutics Inc.

Cambridge, Mass.

$70

Intellia raised $70M in a series B round led by Orbimed Healthcare Fund Management; additional investors included Fidelity Management and Research Co., Janus Capital Management, Foresite Capital, Sectoral Asset Management, Ecor1 Capital and other leading mutual fund and health care investors

9/2/15

Laboratoris Sanifit SL

La Palma, Spain

$41

Laboratoris raised €36.6M (US$41M) in a series C round; investors were Ysios Capital, Lundbeckfond Ventures, Forbion Capital Partners, Gilde Healthcare Partners BV, Edmond de Rothschild Investment Partners, "la Caixa" and Baxter Ventures

9/9/15

Myotherix Inc.

San Jose, Calif.

$1

Myotherix received $1M in an investment from Cureduchenne Ventures LLC

9/2/15

Novadip Biosciences SA

Louvain-La-Neuve, Belgium

$32

Novadip raised €28M (US$31.6M) in a series A round led by New Science Ventures and including Vives Louvain Technology Fund, Nivelinvest, Fund+, Integrale, SRIW, SFPI-FPIM, Epimède and several individual investors

9/11/15

Oncobiologics Inc.

Cranbury, N.J.

$12

Oncobiologics closed an additional round of financing with Sabby Management LLC; the equity financing, along with a prior investment round announced in July, generated $43M in gross proceeds

9/30/15

Replimune Ltd.

Oxford, UK

$30

Replimune raised $30M in a series A round from Forbion Capital Partners, Omega Fund Management LLC; it was led by Atlas Venture

9/25/15

Reviral Ltd.

London

$21

Reviral raised $21M in a series A round

9/9/15

Selecta Biosciences Inc.

Watertown, Mass.

$38

Selecta Biosciences completed a $38M series E round from Orbimed, Sanofi-Genzyme Bioventures – the venture arm of Selecta's partner Paris-based Sanofi SA – Ridgeback Capital Management, Osage University Partners, AJU IB Investment and Sphera Global Health Care Fund, along with participation from all of Selecta's existing investors

9/9/15

Therachon SAS

Nice, France

$35

Therachon raised $35M in a series A round from Versant Ventures and Inserm Transfert Initiative SA; the A round adds two more international investors, lead investor Orbimed and New Enterprise Associates

9/30/15

Various European life sciences firms

Europe

$26

European life sciences firms raised €23M (US$26M) in 42 crowdfunding campaigns; funding went to Apta Biosciences Ltd. (Ledbury, UK; €2.6M), Camnutra Ltd. (Cambridge, UK; €1.3M), Riboxx GmbH (Radebul, Germany; €1M), Cell Therapy Ltd. (Cardiff, UK), Antabio SAS (Labege, France), Wellfundr and Mypharmacompany (France), Aescuvest (Germany), Capital Cell (Spain), and several others

9/8/15

Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.